Papers of note in Science Translational Medicine 9 (415)

This week’s articles describe a way to combat the negative effects of stress on cancer therapy; a potential target in heart failure; and why nighttime wounds heal more slowly than daytime wounds.
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Tags: STKE Editors ' Choice Source Type: news

Related Links:

Purpose of review We aim to summarize the utility of strain in monitoring the effects of cancer therapy-related cardiotoxicity (CTRC) on the development of left ventricular (LV) dysfunction. Recent findings Serial assessment of cardiac function at baseline and during treatment is recommended in patients undergoing cancer treatment. Historically, the use of left ventricular ejection fraction (LVEF) has been used to monitor for cardiac toxicity from cancer therapies but myocardial mechanic parameters, in particular global longitudinal strain (GLS), have emerged as powerful adjunctive tools. On the basis of longitudinal ...
Source: Current Opinion in Cardiology - Category: Cardiology Tags: IMAGING AND HEART FAILURE: MYOCARDIAL STRAIN: Edited by Sherif Nagueh Source Type: research
In this study, we investigate mitochondrial energetics and mtDNA methylation in senescent cells, and evaluate the potential of humanin and MOTS-c as novel senolytics or SASP modulators that can alleviate symptoms of frailty and extend health span by targeting mitochondrial bioenergetics. Exercise versus the Hallmarks of Aging The paper I'll point out today walks through the ways in which exercise is known to beneficially affect the Hallmarks of Aging. The Hallmarks are a list of the significant causes of aging that I dis...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractPurpose of ReviewModern cancer therapy comes at a cost of increased risk of cardiotoxicity. The purpose of our paper is to provide an updated review highlighting research incorporating biomarkers and imaging findings for the detection of subclinical cardiac dysfunction and management of cancer treatment-related cardiotoxicity.Recent FindingsBiomarkers, particularly troponin, NTproBNP, and myeloperoxidase, have been shown to have a predictive role in the development of cancer treatment-related cardiotoxicity. Early reductions in global longitudinal strain and the more recently reported, circumferential strain, have ...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
Due to the success of current treatments, patients are living longer and surviving cancer. However, certain treatments can cause cardiac complications which have a significant impact on the individual... Author: VJHemOnc Added: 06/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
With the increasing life expectancy of cancer patients, the long-term consequences of cancer therapy are becoming an increasing issue. Anthracycline-induced heart failure is a classic example of an ad... Author: VJHemOnc Added: 06/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
AbstractPurpose of reviewWith the continuing development of newer targeted therapies in oncology, it is necessary to understand their potential cardiovascular side effects. In this review, we discuss the association of novel targeted agents and left ventricular systolic dysfunction.Recent findingsWithin the last 5  years, multiple new agents have been developed to target specific cancer pathways and found to have off-targeted cardiotoxicity. The most recent example is the recognition of myocarditis caused by immune checkpoint inhibitors.SummaryThe development of targeted cancer therapies has revolutionized oncology, b...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Authors: Okura Y, Ishigaki S, Sakakibara S, Yumoto C, Hashitate M, Sekine C, Fujita T, Takayama T, Ozaki K, Sato N, Minamino T Abstract Aortic stenosis (AS) is a life-threatening comorbidity of cancer patients. Aortic valve replacement (AVR) should be considered for some cancer patients, but neither the characteristics nor prognosis under conservative therapy is well known.We searched our echocardiography log (years 2005-2014) for cancer patients with AS, and 92 patients (54% female) were included in the study. To compare the survival curves, 470 control patients without AS were selected from our cancer registry.Me...
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Cancer is the second leading cause of death in the United States. Patients with advanced heart failure (AHF) are at increased risk of adverse outcomes during cancer treatment due to their limited cardiac reserve. Active cancer remains an absolute contraindication to heart transplantation; however, LVAD therapy may serve as a valuable option and improve chances of survival during cancer treatment in AHF patients. The aim of this study is to investigate the outcomes of patients with AHF undergoing cancer therapies while on LVAD support.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
AbstractPurpose of ReviewWe aim to summarize the effect of cancer therapy-related cardiotoxicity on the development of left ventricular (LV) dysfunction.Recent FindingsWe discuss commonly used cancer therapeutics that have the potential for both acute and delayed cardiotoxicity. LV dysfunction from cancer therapies may be found by routine cardiac imaging prior to clinical manifestations of heart failure (HF) and we discuss the current multi-modality approaches for early detection of toxicity with the use of advanced echocardiographic parameters including strain techniques. Further, we discuss the role of biomarkers for det...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Environmental Health | Heart | Heart Failure | Science